EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden

Anders Gülfe, Johan K Wallman, Lars Erik Kristensen

7 Citations (Scopus)
49 Downloads (Pure)

Fingerprint

Dive into the research topics of 'EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden'. Together they form a unique fingerprint.

Medicine & Life Sciences